AptarGroup, Inc.
124.31-3.79 (-2.96%)
Oct 29, 4:00:02 PM EDT · NYSE · ATR · USD
Key Stats
Market Cap
8.19BP/E (TTM)
21.47Basic EPS (TTM)
5.79Dividend Yield
0.01%Recent Filings
10-Q
Q2 FY2025 results
AptarGroup posted solid Q2 results, with net sales climbing 6% year-over-year to $966M, fueled by 3% core growth amid a favorable 3% currency tailwind. Operating income rose 15% to $144M, lifting margins to 15.0% from 13.8%, thanks to stronger Pharma and Closures volumes plus better operational efficiency. Diluted EPS hit $1.67, up 25% from $1.34, aligning neatly with 67,048 average shares. Cash from operations dipped to $209M year-to-date, yielding $92M free cash flow after $120M capex, while net debt edged up to $917M against $2.7B equity. A small acquisition wrapped up, adding minor goodwill. Yet competition in beauty and pharma dispensing keeps pressure on pricing.
8-K
Aptar Q2 sales rise 6%
AptarGroup reported Q2 2025 sales up 6% to $966 million, with net income surging 24% to $112 million and adjusted EBITDA climbing 13% to $218 million, boosting margins to 22.6%. Pharma and Closures segments led growth via higher volumes in injectables and food packaging, while Beauty lagged on subdued fragrance launches. All units expanded EBITDA margins. Returned $100 million to shareholders. Q3 adjusted EPS guidance: $1.53-$1.61, tempered by naloxone normalization.
8-K
Plan amendment approved
AptarGroup stockholders approved an amendment to the 2018 Equity Incentive Plan at the May 7, 2025 annual meeting, adding 1,000,000 shares for future grants. All three director nominees sailed through with overwhelming support, while executive pay and auditor ratification passed handily too. This bolsters talent retention amid growth. No hit to current shares outstanding.
10-Q
Q1 FY2025 results
AptarGroup kicked off 2025 with net sales dipping 3% year-over-year to $887.3 million, hit by a 3% currency headwind, though core sales held flat as strong prescription drug volumes offset softer beauty demand. Operating income edged up 1% to $113.4 million, lifting the margin to 12.8% from 12.2%, thanks to cost controls and a favorable pharma mix; diluted EPS slipped to $1.17 from $1.23, aligning with 67.5 million shares. Cash from operations fell to $82.7 million, yielding $25.9 million in free cash flow after $56.9 million capex, while debt eased to $1.01 billion with $136.8 million cash. Restructuring costs dropped to $2.0 million. Yet competition in beauty and closures lingers as a key risk.
8-K
Aptar Q1 sales dip, margins rise
AptarGroup reported Q1 2025 sales of $887 million, down 3% from last year, yet core sales held flat while adjusted EBITDA climbed 3% to $183 million with margins expanding 120 basis points to 20.7%. Pharma's proprietary drug delivery systems grew 2% amid demand for CNS therapies and diabetes tech, while Beauty and Closures dipped on fragrance volumes and tooling. Returned $110 million to shareholders. Q2 adjusted EPS guidance: $1.56-$1.64. Solid margins offset volume softness.
IPO
Website
Employees
Sector
Industry
ABT
Abbott Laboratories
124.43-2.18
ATRC
AtriCure, Inc.
35.44-1.01
AVTR
Avantor, Inc.
11.58-3.50
BAX
Baxter International Inc.
22.42-0.44
COSM
Cosmos Health Inc.
0.93-0.01
RVP
Retractable Technologies, Inc.
0.90-0.01
SHTPY
-
7.65+0.00
STVN
Stevanato Group S.p.A.
25.80+0.02
UFPT
UFP Technologies, Inc.
189.37-8.52
WST
West Pharmaceutical Services, I
284.86+1.37